Baker Bros. Advisors Adds $3M in Wave Life Sciences, Inc. ($WVE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors increased its position in Wave Life Sciences, Inc. ($WVE) by 139.10% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 822,638 shares of Wave Life Sciences, Inc. after buying 478,575 shares during the quarter. Baker Bros. Advisors's holdings in Wave Life Sciences, Inc. were worth $4.83 million as of its most recent filing.
Wave Life Sciences, Inc. Stock Up 16.5%
Shares of Wave Life Sciences, Inc. ($WVE) traded around $5.87 on Saturday, up 16.5% for the day.
Wave Life Sciences, Inc. Earnings
Analysts Set New Price Targets
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Get Wave Life Sciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $WVE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.